These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33559353)

  • 1. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
    Saha D; Ryan KR; Lakkaniga NR; Smith EL; Frett B
    ChemMedChem; 2021 May; 16(10):1605-1608. PubMed ID: 33559353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
    Lakkaniga NR; Gunaganti N; Zhang L; Belachew B; Frett B; Leung YK; Li HY
    Eur J Med Chem; 2020 Nov; 206():112691. PubMed ID: 32823007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.
    Acharya B; Saha D; Garcia Garcia N; Armstrong D; Jabali B; Hanafi M; Frett B; Ryan KR
    Bioorg Med Chem; 2024 May; 106():117749. PubMed ID: 38744018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
    Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
    Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
    Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
    J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
    Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.